Comparative efficacy of pharmacologic therapies for MASLD in improving fibrosis: systematic review and network meta-analysis - PubMed
7 hours ago
- #pharmacologic therapies
- #fibrosis
- #MASLD
- Fibrosis is a key predictor of long-term prognosis in metabolic dysfunction-associated steatotic liver disease (MASLD).
- A systematic review and network meta-analysis compared pharmacologic therapies for MASLD in improving fibrosis using histopathological and noninvasive assessments.
- Primary outcome: more than 1-stage fibrosis improvement; secondary outcomes included changes in liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE) and magnetic resonance elastography.
- Pegozafermin, obeticholic acid (OCA), and resmetirom outperformed placebo in fibrosis stage F1-3 analysis.
- OCA was superior to placebo in the 1.5-year analysis.
- Pegbelfermin (SUCRA: 77.11%) and pegozafermin (SUCRA: 74.91%) at F1-3, and OCA at 1.5 years (SUCRA: 81.64%) were ranked as the most effective treatments.
- Pegozafermin significantly outperformed placebo for decreasing LSM via VCTE in 0.5-year analysis (SUCRA: 96.98%).
- New drugs targeting fibroblast growth factor 21 (FGF21) show potential therapeutic effects for fibrosis improvement in MASLD patients.
- Definitive efficacy will depend on the results of phase III clinical trials.